Gastroenterologia Japonica

, Volume 22, Issue 4, pp 440–447 | Cite as

Pharmacokinetic studies of cimetidine in patients with liver disease

  • Hiroko Yamasaki
  • Terukatsu Arima
  • Hideo Nagashima
Original Article


The tolerability and metabolism of cimetidine administered for over 7 days were studied in 30 patients with liver diseases and 19 control subjects who had peptic ulcers. Cimetidine was well tolerated by these patients without any side effects. The cimetidine in the serum and urine was determined by highperformance liquid chromatography.

The serum cimetidine levels and pharmacokinetic parameters of the patient group did not significantly differ from those of the control group after oral administration. Following intravenous administration, the half-life of cimetidine increased and cimetidine clearance decreased in the liver disease group. These differences seem to be totally explicable by the impaired renal function associated with the liver disease. Furthermore, accumulation of cimetidine in serum did not occur following continuous treatment with cimetidine in these patients.

It was concluded that a reduction of cimetidine dosage is not necessary in patients with liver disease as far as their renal function is not disturbed, since the metabolism of cimetidine was not affected by the liver dysfunction itself.

Key Words

Cimetidine Liver disease Pharmacokinetics 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1).
    Walkenstein SS, et al: Bioavailability of cimetidine in man. Gastroenterology 1978, 74: 360PubMedGoogle Scholar
  2. 2).
    Bodemar G, et al: Pharmacokinetics of cimetidine after single doses and during continuous treatment. Clin Pharmacokinetics 1981, 6: 306CrossRefGoogle Scholar
  3. 3).
    Larsson R, et al: Oral absorption of cimetidine and its clearance in patients with renal failure. Eur J Clin Pharmacol 1979, 15: 153PubMedCrossRefGoogle Scholar
  4. 4).
    Guay DRP, et al: Comparison of bioavailability and pharmacokinetics of cimetidine in subjects with normal and impaired renal function. Clinical Pharmacy 1983, 2: 157PubMedGoogle Scholar
  5. 5).
    Sonne J, et al: Cimetidine clearance and bioavailability in hepatic cirrhosis. Clin Pharmacol Ther 1981, 29: 191PubMedCrossRefGoogle Scholar
  6. 6).
    Okolicsanyi L, et al: Oral and intravenous pharmacokinetics of cimetidine in liver cirrhosis. Int J Clin Pharmacol Ther Toxicol 1982, 20: 482PubMedGoogle Scholar
  7. 7).
    Porro GB, et al: Blood levels of cimetidine in patients with liver cirrhosis. Int J Clin Pharmacol Ther Toxicol 1983, 21: 374Google Scholar
  8. 8).
    Gugler R, et al: Altered disposition and availavility of cimetidine in liver cirrhotic patients. Br J Clin Pharmacol 1982, 14: 421PubMedGoogle Scholar
  9. 9).
    Villeneuve JP, et al: Cimetidine kinetics and dynamics in patients with severe liver disease. Hepatology 1983, 3:923PubMedCrossRefGoogle Scholar
  10. 10).
    Gonzalez-Martin G, et al: Pharmacokinetics of cimetidine in patients with liver disease. Int J Clin Pharmacol Ther Toxicol 1985, 23: 355PubMedGoogle Scholar
  11. 11).
    Guay DRP, et al: High-performance liquid chromatographic analysis of cimetidine in serum and urine. J Chromatogr 1982, 228: 398PubMedCrossRefGoogle Scholar
  12. 12).
    MacDougall BRD, et al: H2-receptor antagonists and antacids in the prevention of acute gastrointestinal hemorrhage in fulminant hepatic failure. Lancet 1977, 1: 617PubMedCrossRefGoogle Scholar
  13. 13).
    Schentag JJ, et al: Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion. Lancet 1979, 1: 177PubMedCrossRefGoogle Scholar
  14. 14).
    Kimelblatt BJ, et al: Dose and serum concentration relationships in cimetidine-associated mental confusion. Gastroenterology 1980, 78: 791PubMedGoogle Scholar
  15. 15).
    Schentag JJ, et al: Age, disease, and cimetidine disposition in healthy subjects and chronically ill patients. Clin Pharmacol Ther 1981, 29: 737PubMedCrossRefGoogle Scholar
  16. 16).
    Burland WL, et al: Pharmacological evaluation of cimetidine, a new histamine H2-receptor antagonist, in healthy man. Br J Clin Pharmacol 1975, 2: 481PubMedGoogle Scholar
  17. 17).
    Taylor DC, et al: The metabolism and elimination of cimetidine, a histamine H2-receptor antagonist, in the rat, dog, and man. Drug Metab Dispos 1978, 6: 21PubMedGoogle Scholar
  18. 18).
    Ma KW, et al: Effects of renal failure on blood levels of cimetidine. Gastroenterology 1978, 74: 473PubMedGoogle Scholar
  19. 19).
    Norlander B, et al: Therapeutic plasma concentrations of cimetidine in normal renal function and dosage requirements in renal failure. Ther Drug Monit 1980, 2: 147PubMedCrossRefGoogle Scholar
  20. 20).
    Drayer DE, et al: Age and renal clearance of cimetidine. Clin Pharmacol Ther 1982, 31: 45PubMedCrossRefGoogle Scholar
  21. 21).
    Kew MC, et al: Renal and intrarenal blood-flow in cirrhosis of the liver. Lancet 1971, 2: 504PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Gastroenterology 1987

Authors and Affiliations

  • Hiroko Yamasaki
    • 1
  • Terukatsu Arima
    • 1
  • Hideo Nagashima
    • 1
  1. 1.First Department of Internal MedicineOkayama University Medical SchoolOkayamaJapan

Personalised recommendations